19 results about "Polyglutamate" patented technology

The application discloses a kind of compound fertilizer with nitrogen fertilizer slow-release and biocontrol function and preparation method, it is related to microbial compound fertilizer field, including the following components: nitrogen source carrier, physical net trapping material, 3,4-dimethyl pyrazole phosphate, biocontrol component, binder.A kind of preparation method, including the following steps: after silanization modification treatment is carried out to attapulgite, with polyglutamic acid aqueous solution mixed reaction, obtain self-assembly gel;Bacillus subtilis is embedded and handled, rhamnolipid is pre-emulsified, chitosan oligosaccharide is crosslinked with boric acid treatment, and is blended;Nitrogen source carrier is heated to melt, add self-assembly gel, mix evenly;Temperature control, add 3,4-dimethyl pyrazole phosphate, and keep warm reaction;Cooling, add the blend obtained in step S200, binder, mix evenly;Extrusion granulation, after fluidized bed drying, slow-release coating is carried out, and the target compound fertilizer is obtained.The application makes disease control efficiency to improve to 89.2%, and blocks nitrosomonas AMO enzyme activity for 120 days.

The invention provides a simple and rapid preparation method of a novel HER2 targeted nano-drug maytansine (DM1). The preparation of the nano-drug is realized by using carboxyl on a side chain of azide-terminated poly (L-glutamic acid) (PLG) as a load binding site. The preparation method comprises the following steps: firstly, grafting N-(2-aminoethyl) maleimide hydrochloride (Mal-C2H4-NH2-HCL) to carboxyl of PLG (Poly L-Glycol), and introducing a maleimide group to form PLG-Mal; the preparation method comprises the following steps: preparing Fc-III-4C peptide-PLG-Mal (Fc-PLG-Mal) by virtue of an amidation reaction between carboxyl and amino of the Fc-III-4C peptide, and then carrying out thiol-maleimide click chemical reaction on a maleimide group and sulfydryl of DM1, so as to obtain the Fc-PLG-DM1. Finally, the HER2 antibody and the Fc-PLG-DM1 are mixed in water by utilizing the high affinity effect between the Fc-III-4C peptide and the Fc segment of the HER2 antibody, so that the HER2-PLG-DM1 can be obtained, and the HER2-PLG-DM1 has a remarkable tumor inhibition effect in animal experiments. The successful development of the HER2-PLG-DM1 proves the potential of the method in the design and development of functional nano-drugs in the future.

In one aspect, a method of treating an NK cell to induce a gene edit. The method may include contacting an NK cell with a transfection composition including poly-L-glutamic acid (y- PGA), a single-stranded oligo deoxynucleotide (ssODN) enhancer, or a combination thereof; contacting the NK cell with an editing composition including: a DNA-PK inhibitor, and an HD AC inhibitor; electroporating the NK cell; and contacting the NK cell with a recovery composition including DNase I. In another aspect, a method of preparing an engineered NK cell comprising a fluorescent reporter at an endogenous locus. In another aspect, a method of treating an NK cell to introduce an exogenous nucleic acid.

The invention provides a preparation method of HER2 targeted composite nanoparticles conjugated with a blood vessel disrupting agent, which comprises the following steps: grafting water-soluble azide-terminated poly (L-glutamic acid) with methoxy polyethylene glycol (NPLG-g-mPEG) to increase the number of effective load binding sites, bonding a cytotoxic drug SN38 with NPLG-g-mPEG through Steglich esterification reaction to obtain N3-PLG-SN38, and then adding the N3-PLG-SN38 into the HER2 targeted composite nanoparticles conjugated with the blood vessel disrupting agent to obtain the HER2 targeted composite nanoparticles conjugated with the blood vessel disrupting agent. According to the present invention, the Fc-PLG-SN38 is obtained by carrying out click chemical bonding on the Fc-III-4C peptide and the N3-PLG-SN38, by using the high affinity between the Fc-III-4C peptide and the Fc of the HER2 antibody, the antibody and the Fc-NPLG-SN38 are mixed in the water environment so as to obtain the HER2-PLG-SN38, and the HER2-PLG-SN38 and the blood vessel disrupting agent CA4P are conjugated so as to enhance the penetrating power and the drug effect on tumor cells;

The disclosure relates generally to alpha polyglutamated aminopterin, formulations containing liposomes filled with alpha polyglutamated aminopterin, methods of making the alpha polyglutamated aminopterin and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated aminopterin and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to polyglutamated alpha tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the polyglutamated alpha tetrahydrofolate, and methods of making and using the polyglutamated alpha tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).

The invention relates to a high-water-solubility denitroflavin-polyglutamic acid compound as well as a preparation method and application thereof, and belongs to the technical field of denitroflavin. The method comprises the following steps: adding the second generation of denitroflavin into an activated sodium polyglutamate solution, adjusting the pH value to 6.8-7.2, then stirring and reacting for 4-6 hours under the water bath condition of 45-55 DEG C, and dialyzing, freeze-drying and grinding to obtain the denitroflavin-polyglutamic acid compound. According to the preparation method, the water solubility of the second generation of denitroflavin is improved by cross-linking the second generation of denitroflavin and sodium polyglutamate for the first time, specifically, the second generation of denitroflavin is added into an activated sodium polyglutamate solution, so that free carboxyl of a side chain of the sodium polyglutamate and active groups of the second generation of denitroflavin are subjected to affinity reaction and multiple cross-linking; a stable three-dimensional network structure is formed, and the second-generation denitrioxanthin is wrapped in the sodium polyglutamate, so that the physical property of the second-generation denitrioxanthin is fundamentally changed to improve the water solubility of the second-generation denitrioxanthin.

This invention discloses a method for preparing passion fruit whole-fruit wine with improved clarification, belonging to the field of food processing technology. In this method, pectinase, cellulase, and transglutaminase are added before fermentation, and polyglutamic acid, bentonite, and curdlan are added after fermentation. The passion fruit whole-fruit wine obtained by this method has a light transmittance as high as 98.9%. The passion fruit wine composite clarifying agent prepared by this invention can be used in the preparation of passion fruit wine from whole passion fruit, significantly improving the clarity of passion fruit wine, reducing the technical difficulty and production cost of the clarification process, shortening the clarification time, effectively maintaining the flavor and nutritional value of the fruit wine, and improving the production efficiency of the fruit wine; it is simple to operate, easy to implement, and worthy of promotion and use.

The invention relates to a temperature / pH dual-response type sodium polyglutamate-hyaluronic acid composite microsphere as well as a preparation method and application thereof, and belongs to the technical field of beauty medicines. Comprising the following steps: (1) mixing a polylactic acid-glycolic acid copolymer, poly (N-isopropylacrylamide) and chitosan to obtain a compound oil phase; (2) mixing polyglutamic acid, hyaluronic acid and RGD-PEG to obtain a functional water phase; (3) mixing the composite oil phase and the functional water phase to obtain W / O / W emulsion; and (4) carrying out selective crosslinking on the W / O / W emulsion, and then carrying out deep crosslinking to obtain the composite microspheres. The composite microsphere prepared by the invention has a temperature / pH double-response function, can shrink and release the active pharmaceutical ingredients in a skin inflammation high-temperature area after loading the active pharmaceutical ingredients, and also can accelerate degradation and release the active pharmaceutical ingredients in a weak acid environment.

To provide a gamma-polyglutamate oxidase folate antagonist composition that can overcome pharmacological challenges related to dose-limiting toxicity and therapeutic resistance associated with folate antagonist therapy. [Solution] A liposome composition (Lp-γPANTIFOL composition) containing a gamma polyglutamine oxidized folate antimetabolitic agent, wherein the gamma polyglutamine oxidized folate antimetabolitic agent contains 2 to 15 glutamyl groups, and the liposomes are pegylated.

The present disclosure relates generally to polyglutamic acid-modified antifolate agents, formulations containing liposomes filled with alpha or D-gamma polyglutamic acid-modified antifolate agents, methods of making polyglutamic acid-modified antifolate agents and liposomal-containing formulations, and methods of treating myeloproliferative disorders (e.g., cancer) and immune system disorders (e.g., autoimmune diseases, such as rheumatoid arthritis) using the polyglutamic acid-modified antifolate and the liposomal-containing formulations.

The present application relates to the technical field of adhesive, in particular to an adhesive, a preparation method thereof and a self-adhesive flexible electrode. Sodium polyglutamate is dissolved in water to obtain a first solution. A modifying agent is dissolved in water to obtain a second solution, so that the modifying agent dissociates to form halogen ions and modifying ions, the modifying ions include N + groups connected with three substituents, and the group at the distal end is a long-chain alkyl with a chain length greater than or equal to 8. The first solution and the second solution are mixed, the precipitate is collected and dried to obtain an adhesive substance. The adhesive substance forms a viscous layer and is compounded with a flexible and conductive electrode layer to form a self-adhesive flexible electrode. Since polyglutamic acid has high biocompatibility, the N + group has a sterilization effect, and the long-chain alkyl has a hydrophobic effect, the adhesive has good biological affinity, antibacterial property and waterproof property, and also has strong adhesive capacity, which facilitates the stable adhesion of the self-adhesive flexible electrode to the skin surface, does not damage the skin and accurately outputs bioelectric signals.

This invention relates to the field of balloon technology, and discloses a functional balloon, its preparation method, and its application. The surface of the functional balloon is loaded with polyglutamic acid, which is linked to a DNA hydrogel via amide bonds. A nucleotide sequence is linked to the DNA hydrogel and thrombin. The balloon obtained by this invention can achieve hemostasis and reduce bleeding symptoms without vascular occlusion.

The disclosure relates generally to gamma polyglutamated methotrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated methotrexate, and methods of making and using the gamma polyglutamated methotrexate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).

The invention discloses a gamma-PGA synthetase gene cluster pgsBCA '. The gamma-PGA synthetase gene cluster pgsBCA' is formed by sequentially connecting genes pgsB, pgsC and pgsA 'in series, the genes pgsB and pgsC are derived from a gamma-PGA synthetase gene cluster BA-pgsBCA of the bacillus altitudinis; the gene pgsA'is derived from a gamma-PGA synthetase gene cluster BM-pgsB 'C' A 'of bacillus megatherium. Bacillus amyloliquefaciens CF of which a genome knockout polyglutamate synthetase gene cluster is used as a host, and a recombinant polyglutamate synthetase gene cluster pgsBCA'is subjected to free expression through plasmids, so that a gene engineering strain capable of synthesizing gamma-L-PGA is obtained. When the strain is used for producing gamma-L-PGA in a 5L fermentation tank through amplification fermentation, the maximum yield can reach 10.5 g / L. Besides, the gamma-poly-L-glutamic acid is free of cytotoxicity and low in immunogenicity, so that the gamma-poly-L-glutamic acid has a wide application prospect in the fields of preparation of wound dressings, in-vivo absorption materials and the like. The invention provides a new material basis and technical support for application and development of polyglutamic acid in the fields of medicine and related biomedicine.

The invention discloses a polyglutamic acid degrading enzyme BaPgdS derived from bacillus aerophilus NQPG-1 as well as a coding gene and application of the polyglutamic acid degrading enzyme BaPgdS. The BaPgdS enzyme disclosed by the invention has definite degradation activity on gamma-PGA with a whole series configuration, wherein the molar ratio of D-glutamic acid in the gamma-PGA is 0-97%; the degradation effect on gamma-PGA with the mole ratio of D-glutamic acid being 97% is most prominent, and the weight-average molecular weight of gamma-PGA can be reduced from about 2000 kDa to about 3 kDa. Further, a gene for coding the enzyme is over-expressed in wild type bacillus aerophilus, and the constructed bacillus aerophilus genetically engineered bacterium can reduce the molecular weight of gamma-PGA synthesized by self fermentation to about 20 kDa. Through systematic full-configuration substrate testing, the invention provides a degrading enzyme with wider substrate universality, and provides a new tool for degradation of gamma-PGA with different configurations and direct fermentation production of gamma-PGA with small molecular weight.

The present application is directed to antimicrobial compositions, comprising chitosan having an average molecular weight (Mw) of about 2 to about 100 kDa, an organic acid; and an additive selected from gum arabic, maltodextrin, gellan gum, guar gum, xanthan gum, psyllium, polyglutamate, carrageenan, pectin, alginate, hyaluronic acid, dextran, chondroitin, polyphosphate, and combinations thereof. The present application also includes a method of stabilizing and / or preserving a food or beverage product and a method of inhibiting growth of one or more microorganisms in the food or beverage product comprising adding an effective amount of one or more compositions of the application to the product.

The invention discloses a method for affinity separation and purification of serratiolysin extracellular metalloproteinase based on polyglutamic acid, and belongs to the technical field of bioengineering. According to the method, the characteristic that the serratiolysin extracellular metalloproteinase contains seven calcium ion binding sites is utilized, polyglutamic acid is taken as a specific polycarboxylic acid ligand, directional capture of target protease is realized through calcium ion mediated coordination, and the steps of gradient elution and the like are combined, so that the high-purity serratiolysin extracellular metalloproteinase is finally obtained. The purification multiple reaches 6.8 times, the recovery rate is 85.2%, the electrophoresis purity is larger than or equal to 99%, and the method is mild in operation, low in cost and suitable for industrial production.